[{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Johannes Levin","sponsor":"German Center for Neurodegenerative Diseases | Deutsche Parkinson Vereinigung | German Foundation for Neurology | ParkinsonFonds Deutschland gGmbH","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase; Signal transducer and activator of transcription 3; Gag-Pol polyprotein; Matrix metalloproteinase-14; 72 kDa type IV collagenase; Squalene monooxygenase; Neutrophil elastase; Protein-glutamine gamma-glutamyltransferase 2; Aryl hydrocarbon receptor; DNA (cytosine-5)-methyltransferase 1; Dihydrofolate reductase 2, mitochondrial","graph1":"Neurology","graph2":"Phase III","graph3":"Dr. Johannes Levin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Johannes Levin \/ German Center for Neurodegenerative Diseases | Deutsche Parkinson Vereinigung | German Foundation for Neurology | ParkinsonFonds Deutschland gGmbH","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Johannes Levin \/ German Center for Neurodegenerative Diseases | Deutsche Parkinson Vereinigung | German Foundation for Neurology | ParkinsonFonds Deutschland gGmbH"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase (FASN)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase (FASN)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase (FASN)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Taipei Medical University","sponsor":"Eagletek Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Taipei Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taipei Medical University \/ Eagletek Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Taipei Medical University \/ Eagletek Corp."},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"AMOREPACIFIC CORPORATION","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seoul National University Hospital \/ AMOREPACIFIC CORPORATION","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ AMOREPACIFIC CORPORATION"},{"orgOrder":0,"company":"Liverpool John Moores University","sponsor":"Unilever","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Liverpool John Moores University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Liverpool John Moores University \/ Unilever","highestDevelopmentStatusID":"1","companyTruncated":"Liverpool John Moores University \/ Unilever"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Charles Drew University of Medicine and Science","sponsor":"National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Charles Drew University of Medicine and Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles Drew University of Medicine and Science \/ National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Charles Drew University of Medicine and Science \/ National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li. Pharma International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lo.Li. Pharma International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lo.Li. Pharma International \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lo.Li. Pharma International \/ Undisclosed"},{"orgOrder":0,"company":"Pharmass\u00eatX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Pharmass\u00eatX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmass\u00eatX \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Pharmass\u00eatX \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Biotech S.r.l.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Adamas Biotech S.r.l.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adamas Biotech S.r.l. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Adamas Biotech S.r.l. \/ Undisclosed"},{"orgOrder":0,"company":"Activ'inside","sponsor":"Complife Italia Srl","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Activ'inside","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Activ'inside \/ Complife Italia Srl","highestDevelopmentStatusID":"1","companyTruncated":"Activ'inside \/ Complife Italia Srl"}]
Find Clinical Drug Pipeline Developments & Deals for (-)-Epigallocatechin gallate
Details :
Green Tea Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation-associated with Irritable Bowel Syndrome.
Details :
Green Tea is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypercholesterolemia.
Details :
Green Tea is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Details :
Green Tea Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Details :
Green Tea Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Alopecia.
Details :
PSX-514 (epigallocatechin gallate) is a small molecule, amyloid precursor protein (APP) inhibitor indicated for the treatment of inflammatory bowel disease pouchitis.
Details :
Epigallocatechin Gallate is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Papillomavirus Infections.
Details :
Phase III Adult Stem Cell Company Covers Ability of its COVID-19 Nutraceutical to Repair Injured Brain Cells and Stimulate Endogenous Brain Stem Cells comprising administration of green tea and/or an extract.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
November 28, 2022
Lead Product(s) : Green Tea Extract,Broccoli Extract,Nigella Sativa Extract
Details :
Epigallocatechin Gallate is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Papilloma.
Details :
Pervistop (Epigallocatechin Gallate) once-daily supplement provides a true alternative to eradicating the root problem of HPV persistence, which can unpredictably evolve into cancer.
Reset All
